A Lateral Flow Assay (LFA) is a paper-based diagnostic format that detects a target analyte in a liquid sample without requiring laboratory infrastructure, instrumentation, or a trained operator. Sample fluid migrates across a porous membrane by capillary action, where labeled antibodies interact with capture reagents to produce a visible test line. Most LFAs deliver results within 5–30 minutes and are widely used for rapid point-of-care and self-testing applications.
What is a Lateral Flow Assay (LFA)?
A Lateral Flow Assay (LFA), also known as a lateral flow immunochromatographic assay, combines two well-established analytical principles: chromatography, which moves liquid through a porous membrane by capillary action, and immunoassay chemistry, where antibodies or other affinity molecules selectively bind a target analyte.
LFAs form one of the largest categories of in vitro diagnostic (IVD) devices. Common examples include home pregnancy tests, rapid respiratory virus antigen tests, malaria tests, cardiac biomarker assays, and numerous infectious disease screening products.
Within a medical device development program, an LFA integrates multiple engineering disciplines. Assay chemistry defines sensitivity and specificity, materials engineering determines membrane performance and fluid flow, industrial design shapes the cartridge, and manufacturing engineering ensures consistent strip production across millions of devices. Once design verification begins, changes to reagents, membranes, or strip architecture become controlled design changes requiring documented evaluation.
Why Lateral Flow Assay (LFA) matters in medical device development
LFA performance directly influences clinical decision-making. False-negative results can delay treatment or infection control measures, while false-positive results may lead to unnecessary follow-up testing, anxiety, or treatment. Since many LFAs are used outside laboratory environments without confirmatory testing, the analytical performance of the strip itself becomes the primary determinant of patient safety.
Regulatory authorities therefore evaluate LFAs as regulated IVD medical devices rather than simple consumer products. Under the EU In Vitro Diagnostic Regulation (IVDR), classification depends on intended use and public health impact, with many self-testing or infectious disease assays falling into Class C or Class D. In the United States, most LFAs are reviewed through the FDA’s 510(k) process, with many manufacturers also pursuing CLIA Waiver status for decentralized testing.
Even seemingly minor manufacturing changes—such as switching antibody suppliers, modifying membrane materials, or adjusting conjugate formulations—can alter analytical performance enough to require additional verification, stability testing, and, in some cases, updated regulatory submissions.
How the Lateral Flow Assay (LFA) works
A standard lateral flow strip consists of several functional components laminated onto a backing card.
- Sample pad. Accepts the patient sample while filtering debris and conditioning the fluid before it enters the assay.
- Conjugate pad. Contains dried detection reagents, typically antibodies labeled with colloidal gold nanoparticles, colored latex beads, fluorescent particles, or other reporter molecules. These reagents dissolve when the sample reaches the pad.
- Nitrocellulose membrane. The central analytical region contains the immobilized test and control lines. This membrane strongly influences assay sensitivity and reproducibility.
- Test line. Immobilized capture molecules bind the analyte-reporter complex when the target is present (or absent, depending on assay design), producing the visible analytical signal.
- Control line. Captures excess labeled conjugate regardless of analyte concentration, confirming that sufficient sample migrated through the strip and that the assay functioned correctly.
- Absorbent pad. Maintains capillary flow by continuously drawing liquid across the membrane while preventing reverse flow.
Development follows established medical device design controls. User needs to define the intended analyte, specimen type, clinical cutoff, and use environment. Analytical verification establishes sensitivity, specificity, precision, cross-reactivity, interference, and limit of detection. Clinical validation demonstrates performance in the intended patient population.
Quality management follows ISO 13485, while risk management is performed under ISO 14971 to address hazards such as false negatives, weak control lines, invalid results, or incorrect user interpretation. Performance evaluation studies commonly follow EN 13612 alongside IVDR performance evaluation requirements.
Common challenges and best practices
Lot-to-lot manufacturing variation remains one of the biggest technical challenges in LFA production. Variations in antibody conjugation efficiency, nitrocellulose membrane characteristics, striping precision, or environmental humidity can alter line intensity sufficiently to affect borderline clinical results. Robust in-process controls and quantitative optical inspection significantly improve manufacturing consistency.
Matrix effects represent another major challenge. Whole blood, serum, plasma, saliva, nasal swabs, and urine all behave differently, influencing analyte recovery and flow dynamics. Analytical validation performed only in buffer or contrived samples often fails to predict real-world performance. Well-designed clinical studies therefore include representative patient specimens covering the intended use population.
Shelf-life claims require similarly rigorous evidence. Accelerated aging alone is insufficient; manufacturers must demonstrate reagent stability, packaging performance, desiccant effectiveness, and transport robustness under expected environmental conditions throughout the labeled storage period.
Programs that perform best integrate assay development, cartridge engineering, manufacturing process development, and regulatory planning from the earliest feasibility stages rather than treating them as sequential activities.
How SJML helps with Lateral Flow Assay (LFA)
SJML supports lateral flow diagnostic programs from early feasibility through commercial manufacturing. Multidisciplinary teams work across assay development, microfluidics, electromechanical engineering, industrial design, embedded electronics for reader-integrated systems, and manufacturing process development.
Manufacturing capabilities include medical-grade plastics, precision tooling, cleanroom assembly, automated strip production, and IQ/OQ/PQ process validation to ensure consistent performance at production scale. SJML’s QARA team supports FDA 510(k), EU IVDR technical documentation, device classification, analytical performance planning, and post-market surveillance, helping manufacturers move rapid diagnostic products efficiently from concept through commercialization.
Talk to SJML’s diagnostics team →
Frequently asked questions
In most cases, yes. Lateral Flow Assay describes the underlying analytical technology, while “rapid test” refers to the commercial product. Many home pregnancy tests, infectious disease antigen tests, and point-of-care diagnostic strips use lateral flow technology, making the two terms nearly synonymous in everyday practice.
Most lateral flow assays are regulated as Class II in vitro diagnostic devices and are reviewed through the FDA 510(k) pathway under the applicable sections of 21 CFR Parts 862, 864, or 866, depending on the intended analyte. Manufacturers seeking use in physician offices, pharmacies, or home settings often pursue a CLIA Waiver alongside the 510(k) through a Dual Submission process.
Classification depends on intended use and risk according to Annex VIII of Regulation (EU) 2017/746. Routine diagnostic assays may fall into Class B, while self-testing devices, companion diagnostics, and tests for high-consequence infectious diseases frequently fall into Class C or Class D, requiring Notified Body involvement and more extensive performance evaluation.
False-negative results commonly arise when analyte concentrations fall below the assay’s limit of detection, from sample matrix interference, improper specimen collection, or degradation of assay reagents during storage. False-positive results may result from antibody cross-reactivity, nonspecific binding, interfering substances, or interpreting the strip outside the manufacturer’s specified read window.
Standard visually interpreted LFAs are generally qualitative or semi-quantitative. However, the same strip can generate quantitative measurements when paired with an optical reader that measures reflectance, fluorescence, chemiluminescence, or color intensity. Quantitative LFA systems are increasingly used for cardiac biomarkers, inflammatory markers, and infectious disease testing in clinical settings.
Related terms
- Point-of-Care Testing (POCT)
- In Vitro Diagnostic (IVD) Device
- Analytical Validation
- CLIA Waiver
- EU IVDR Classification
